SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-007874
Filing Date
2022-05-05
Accepted
2022-05-05 16:32:37
Documents
95
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q bbio-20220331.htm   iXBRL 10-Q 3900877
2 EX-31.1 bbio-ex31_1.htm EX-31.1 32365
3 EX-31.2 bbio-ex31_2.htm EX-31.2 32483
4 EX-32.1 bbio-ex32_1.htm EX-32.1 15156
5 EX-32.2 bbio-ex32_2.htm EX-32.2 15469
  Complete submission text file 0000950170-22-007874.txt   16172091

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT bbio-20220331_pre.xml EX-101.PRE 652063
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT bbio-20220331_cal.xml EX-101.CAL 88466
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT bbio-20220331_def.xml EX-101.DEF 470893
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT bbio-20220331_lab.xml EX-101.LAB 832926
10 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT bbio-20220331.xsd EX-101.SCH 119144
89 EXTRACTED XBRL INSTANCE DOCUMENT bbio-20220331_htm.xml XML 3456420
Mailing Address 421 KIPLING STREET PALO ALTO CA 94301
Business Address 421 KIPLING STREET PALO ALTO CA 94301 (650) 391-9740
BridgeBio Pharma, Inc. (Filer) CIK: 0001743881 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38959 | Film No.: 22896935
SIC: 2834 Pharmaceutical Preparations